Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Samsung Medical Center1 site in 1 country51 target enrollmentJuly 2006

ConditionsNasopharyngeal Cancer

InterventionsDocetaxel, Cisplatin

DrugsDocetaxel, Cisplatin

Overview

Phase: Phase 2
Intervention: Docetaxel, Cisplatin
Conditions: Nasopharyngeal Cancer
Sponsor: Samsung Medical Center
Enrollment: 51
Locations: 1
Primary Endpoint: objective response rate
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Registry

clinicaltrials.gov

Start Date

July 2006

End Date

May 2011

Last Updated

15 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

•histologically confirmed nasopharyngeal cancer
•chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
•at least one measurable lesion